Novo Nordisk more than doubled the Danish drugmaker’s target for sales of obesity medicines by 2025 after overwhelming demand for the company’s new Wegovy product.
Mylan has come under fire from the U.S. Food and Drug Administration over inadequate good manufacturing practices at one of the company’s drug manufacturing facilities in India.
